MedTrace Logo

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

NCT04300803 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2020-08-28

No results posted yet for this study

Summary

Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with relapsed or refractory Diffuse Large B Cell Lymphoma. Access to MorphoSys´ EAP can be requested by contacting the respective CRO Clinigen ([email protected]).

Conditions

Interventions

BIOLOGICAL

Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression

Expanded Access Program, Non-Interventional Study

Sponsors & Collaborators

  • Clinigen Healthcare Ltd

    collaborator UNKNOWN

  • MorphoSys AG

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04300803 on ClinicalTrials.gov